Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ThisCART 22

X
Drug Profile

ThisCART 22

Alternative Names: Allogeneic CAR-T targeting CD22; ThisCART-22; ThisCART22 cells

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Fundamenta Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported B-cell lymphoma

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in B-cell lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral, Infusion)
  • 25 Oct 2021 Fundamenta Therapeutics initiates enrolment in a phase I trial for B-cell lymphoma (In the elderly, In adults, Second-line therapy) in China (Parenteral) (NCT05106946)
  • 29 Oct 2020 Fundamenta Therapeutics has patent protection for allogenic CAR-T cells globally
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top